Table 2.
Comparison between patients who received alteplase and those who received placebo in the group of patients with an infratentorial stroke localization.
| Alteplase N = 22 | Placebo N = 26 | ||
|---|---|---|---|
| Mean age (years) (SD) | 62.6 (10.3) | 57.7 (13.5) | p = 0.230 |
| Gender (male), N (%) | 20 (90.9%) | 21 (80.8%) | p = 0.429 |
| Median symptom recognition to start of treatment (hours) (IQR) | 3.1 (2.6–3.6) | 3.5 (2.9–4.0) | p = 0.272 |
| Arterial hypertension, N (%) | 12 (54.6%) | 13 (50.0%) | p = 0.780 |
| Diabetes mellitus, N (%) | 7 (31.8%) | 3 (11.5%) | p = 0.152 |
| Atrial fibrillation, N (%) | 1 (4.6%) | 0 (0.0%) | p = 0.205 |
| Hypercholesterolemia, N (%) | 11 (50.0%) | 7 (26.9%) | p = 0.138 |
| Median NIHSS at baseline (IQR) | 5.0 (3.0–8.0) | 4.0 (3.0–5.0) | p = 0.295 |
| Median NIHSS at 7 days post-stroke (IQR) | 1.5 (0.0–6.0) | 2.0 (1.0–4.0) | p = 0.580 |
| Median stroke volume at baseline (ml) (IQR) | 0.8 (0.2–1.9) | 0.7 (0.3–1.3) | p = 0.820 |
| Median stroke volume at follow up (ml) (IQR) | 0.8 (0.3–3.1) | 0.9 (0.4–3.1) | p = 0.656 |
Follow up was 22–36 h after treatment.